If you have any questions for next week's webinar guest speakers (Pyx Resources, Helix Exploration, Fulcrum Metals and Metals One), please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick pickshVIVO Regulatory News (HVO)

Share Price Information for hVIVO (HVO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 30.60
Bid: 30.20
Ask: 31.00
Change: 0.20 (0.66%)
Spread: 0.80 (2.649%)
Open: 30.25
High: 30.60
Low: 30.40
Prev. Close: 30.30
HVO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EUR3.2m Venn contract with global pharma client

17 Jan 2023 07:00

RNS Number : 8912M
hVIVO PLC
17 January 2023
 

 

hVIVO plc

("hVIVO" or the "Company")

 

€3.2m contract for Venn Life Sciences with global pharmaceutical client

For provision of pharmacokinetic and programming services

 

hVIVO plc (AIM & Euronext: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its consultancy services division, Venn Life Sciences ("Venn"), has signed a contract with a major global pharmaceutical client worth €3.2m over two years.

 

The contract commences in January 2023, with the Venn team in Breda providing dedicated complex clinical pharmacokinetics ("PK") consultancy and programming services to this global pharmaceutical client on a number of drug development programmes across multiple therapeutic areas, to study the absorption, distribution and excretion of drugs within the body.

 

Venn has nearly 30 experts dedicated to providing PK and programming services to clients and has been a trusted partner to the pharma industry for over 25 years. These services cover a diverse range of trials and therapeutic areas ranging from traditional phase I trials to more complex and challenging trials, such as oncology and ATMP (Advanced Therapy Medicinal Product) trials. Venn is a leader in providing fully integrated drug development services from early drug discovery to clinical trials. Its offering includes drug development consultancy, clinical trial design and execution services with expertise and capabilities in CMC (Chemistry, Manufacturing and Controls), Non-Clinical, Clinical Pharmacology and Development, Statistics, Study Design and Methodology, Data Management, Medical Writing and Regulatory Affairs. These combined services enable Venn to provide its clients with a complete end-to-end service on all stages of their drug development programmes, from the early planning phase to final execution. Venn has offices in Breda (Netherlands) and Paris (France).

 

Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said: "The consultancy work included in this two-year contract highlights the continued expansion of our pharmacokinetic and programming services as part of Venn's integrated drug development services provision. Venn's outstanding expertise and reputation in the industry over the past 25 years makes them a go-to partner. In addition, for infectious disease products, hVIVO and Venn have also been able to conduct projects from discovery to Phase II Challenge Studies, something no one else can offer."

 

Dr Katsuhiro Mihara, Head of Clinical Development of Venn Life Sciences, commented: "This contract is a great example of Venn's ability to deliver on long term PK and programming projects. We have worked closely with hVIVO to identify ways to leverage this strong client base, to drive both upselling and cross-selling opportunities, and find even greater synergies between the two integrated clinical services businesses."

 

For further information please contact:

 

hVIVO plc

+44 (0) 20 7756 1300

Yamin 'Mo' Khan, Chief Executive Officer

Stephen Pinkerton, Chief Financial Officer

Liberum Capital (Nominated Adviser and Joint Broker)

 +44 (0) 20 3100 2000

Ben Cryer, Edward Mansfield, Phil Walker, Will King

finnCap plc (Joint Broker)

+44 (0) 20 7220 0500

Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

Davy (Euronext Growth Adviser and Joint Broker)

+353 (0) 1 679 6363

Anthony Farrell, Niall Gilchrist

Walbrook PR (Financial PR & IR)

Stephanie Cuthbert / Phillip Marriage /Louis Ashe-Jepson

+44 (0) 20 7933 8780 or hvivo@walbrookpr.com

+44 (0) 7796 794 663 / +44 (0) 7867 984 082 /+44 (0) 7747 515 393

 

 

Notes to Editors

 

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

 

The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

 

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABRGDBUDBDGXL
Date   Source Headline
17th Jul 20247:01 amRNSHolding(s) in Company
17th Jul 20247:00 amRNSTrading update
8th Jul 20247:00 amRNSHolding(s) in Company
3rd Jul 20242:48 pmRNSHolding(s) in Company
2nd Jul 20247:02 amRNSChange of registered address
2nd Jul 20247:01 amRNSCapital Markets Day & Notice of trading update
2nd Jul 20247:00 amRNSInfluenza 2b field study contract
3rd Jun 20247:00 amRNS£2.5m contract for Omicron characterisation study
13th May 20241:02 pmRNSResult of AGM
15th Apr 20247:00 amRNSAnnual Report & Notice of AGM
9th Apr 20247:09 amRNSFinal results
27th Mar 20247:00 amRNSNotice of Results
22nd Mar 20243:03 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSHolding(s) in Company
15th Feb 20247:00 amRNSLong Term Incentive Plan / PDMR Notification
14th Feb 20241:14 pmRNSResult of Secondary Placing
14th Feb 20247:00 amRNSProposed Secondary Placing of Ordinary Shares
2nd Feb 202412:44 pmRNSHolding(s) in Company
30th Jan 20247:00 amRNSTrading update
8th Jan 20247:00 amRNSBroker change
2nd Jan 20247:00 amRNS£6.3m HRV contract signed with biotech client
13th Dec 20237:00 amRNS£16.8m RSV contract & Trading ahead of guidance
5th Oct 20237:00 amRNSPositive results from flu human challenge study
12th Sep 20237:00 amRNSInterim results
1st Sep 20237:00 amRNSExercise of Warrants
29th Aug 20237:00 amRNSPlans for a new larger state-of-the-art facility
24th Aug 20237:00 amRNSNotice of Results
26th Jul 20237:00 amRNSTrading update
25th Jul 20237:00 amRNSFlu B challenge model
28th Jun 20237:00 amRNShMPV human challenge model
14th Jun 20238:00 amRNSDirector dealings
23rd May 202312:36 pmRNSResult of AGM
28th Apr 20237:00 amRNSAnnual Report and Notice of AGM
26th Apr 20237:00 amRNSFDA Breakthrough and Fast Track for US biotech
25th Apr 20237:00 amRNSFinal results
19th Apr 20237:10 amRNSNotice of Results
6th Apr 20233:54 pmRNSHolding(s) in Company
3rd Apr 20237:00 amRNSPositive results from flu human challenge study
29th Mar 20237:00 amRNSPresentation at World Vaccine Congress
23rd Mar 20237:00 amRNSExercise of Options
16th Mar 20237:00 amRNSOmicron human challenge model update
6th Feb 20239:05 amRNSSecond Price Monitoring Extn
6th Feb 20239:00 amRNSPrice Monitoring Extension
6th Feb 20237:05 amRNSLong Term Incentive Plan / PDMR Notification
6th Feb 20237:00 amRNS£6.8m RSV human challenge contract signed
25th Jan 20239:06 amRNSSecond Price Monitoring Extn
25th Jan 20239:00 amRNSPrice Monitoring Extension
25th Jan 20237:00 amRNSTrading update
17th Jan 20237:00 amRNSEUR3.2m Venn contract with global pharma client
4th Jan 20234:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.